Near-infrared Image Guided Surgery in Pancreatic Adenocarcinoma
Status:
Terminated
Trial end date:
2018-05-01
Target enrollment:
Participant gender:
Summary
There is a need for better visualization of resection margins and detection of small tumor
deposits during surgery for pancreatic cancer. Optical molecular imaging of pancreatic ductal
adenocarcinoma associated biomarkers is a promising technique to accommodate this need. The
biomarker Vascular Endothelial Growth Factor (VEGF-A) is overexpressed in pancreatic cancer
tissue versus normal tissue and has proven to be a valid target for molecular imaging. VEGF-A
can be targeted by the monoclonal antibody bevacizumab. Monoclonal antibodies can be labeled
by the near-infrared (NIR) fluorescent dye IRDye800CW (800CW). The investigators hypothesize
that bevacizumab-800CW accumulates in VEGF expressing cancer, enabling pancreatic cancer
visualization using a NIR intraoperative camera system. In this pilot intervention study the
investigators will determine the optimal dosage of bevacizumab-800CW (4,5 10, 25 or 50mg) to
detect pancreatic cancer tissue intraoperatively.